{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:33:02Z","timestamp":1793647982447,"version":"4.5.1"},"reference-count":206,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T00:00:00Z","timestamp":1604966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1038\/s41571-020-00442-4","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T11:02:41Z","timestamp":1605006161000},"page":"152-169","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":270,"title":["The nuclear export protein XPO1 \u2014 from biology to targeted therapy"],"prefix":"10.1038","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1178-9505","authenticated-orcid":false,"given":"Asfar S.","family":"Azmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0188-6857","authenticated-orcid":false,"given":"Mohammed H.","family":"Uddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi M.","family":"Mohammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,10]]},"reference":[{"key":"442_CR1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/nar\/gkp089","volume":"37","author":"EV Koonin","year":"2009","unstructured":"Koonin, E. V. Darwinian evolution in the light of genomics. Nucleic Acids Res. 37, 1011\u20131034 (2009).","journal-title":"Nucleic Acids Res."},{"key":"442_CR2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.biochi.2015.03.021","volume":"119","author":"T Gabaldon","year":"2015","unstructured":"Gabaldon, T. & Pittis, A. A. Origin and evolution of metabolic sub-cellular compartmentalization in eukaryotes. Biochimie 119, 262\u2013268 (2015).","journal-title":"Biochimie"},{"key":"442_CR3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3324\/haematol.2012.074781","volume":"98","author":"AS Azmi","year":"2013","unstructured":"Azmi, A. S. et al. Selective inhibitors of nuclear export for the treatment of non-Hodgkin\u2019s lymphomas. Haematologica 98, 1098\u20131106 (2013).","journal-title":"Haematologica"},{"key":"442_CR4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0092-8674(00)80370-0","volume":"90","author":"K Stade","year":"1997","unstructured":"Stade, K., Ford, C. S., Guthrie, C. & Weis, K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 90, 1041\u20131050 (1997).","journal-title":"Cell"},{"key":"442_CR5","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1200\/JCO.2016.67.5637","volume":"34","author":"AS Azmi","year":"2016","unstructured":"Azmi, A. S. & Mohammad, R. M. Targeting cancer at the nuclear pore. J. Clin. Oncol. 34, 4180\u20134182 (2016).","journal-title":"J. Clin. Oncol."},{"key":"442_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2014.04.011","volume":"27","author":"AS Azmi","year":"2014","unstructured":"Azmi, A. S. The evolving role of nuclear transporters in cancer. Semin. Cancer Biol. 27, 1\u20132 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"442_CR7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1042\/BJ20150368","volume":"468","author":"M Soniat","year":"2015","unstructured":"Soniat, M. & Chook, Y. M. Nuclear localization signals for four distinct karyopherin-beta nuclear import systems. Biochem. J. 468, 353\u2013362 (2015).","journal-title":"Biochem. J."},{"key":"442_CR8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pharmthera.2016.03.020","volume":"164","author":"A Mahipal","year":"2016","unstructured":"Mahipal, A. & Malafa, M. Importins and exportins as therapeutic targets in cancer. Pharmacol. Ther. 164, 135\u2013143 (2016).","journal-title":"Pharmacol. Ther."},{"key":"442_CR9","doi-asserted-by":"crossref","first-page":"21289","DOI":"10.18632\/oncotarget.25088","volume":"9","author":"DM Saulino","year":"2018","unstructured":"Saulino, D. M., Younes, P. S., Bailey, J. M. & Younes, M. CRM1\/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity. Oncotarget 9, 21289\u201321295 (2018).","journal-title":"Oncotarget"},{"key":"442_CR10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-30686-1","volume":"8","author":"VV Subhash","year":"2018","unstructured":"Subhash, V. V. et al. Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor. Sci. Rep. 8, 12248 (2018).","journal-title":"Sci. Rep."},{"key":"442_CR11","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1936-z","volume":"15","author":"GL Gravina","year":"2015","unstructured":"Gravina, G. L. et al. KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models. BMC Cancer 15, 941 (2015).","journal-title":"BMC Cancer"},{"key":"442_CR12","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.31557\/APJCP.2019.20.12.3747","volume":"20","author":"M Aladhraei","year":"2019","unstructured":"Aladhraei, M., Kassem Al-Thobhani, A., Poungvarin, N. & Suwannalert, P. Association of XPO1 overexpression with NF-kappaB and Ki67 in colorectal cancer. Asian Pac. J. Cancer Prev. 20, 3747\u20133754 (2019).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"442_CR13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013241","volume":"5","author":"N Neumann","year":"2010","unstructured":"Neumann, N., Lundin, D. & Poole, A. M. Comparative genomic evidence for a complete nuclear pore complex in the last eukaryotic common ancestor. PLoS ONE 5, e13241 (2010).","journal-title":"PLoS ONE"},{"key":"442_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/febs.13163","volume":"282","author":"B Cautain","year":"2015","unstructured":"Cautain, B., Hill, R., de Pedro, N. & Link, W. Components and regulation of nuclear transport processes. FEBS J. 282, 445\u2013462 (2015).","journal-title":"FEBS J."},{"key":"442_CR15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1146\/annurev-biochem-060109-151030","volume":"80","author":"A Hoelz","year":"2011","unstructured":"Hoelz, A., Debler, E. W. & Blobel, G. The structure of the nuclear pore complex. Annu. Rev. Biochem. 80, 613\u2013643 (2011).","journal-title":"Annu. Rev. Biochem."},{"key":"442_CR16","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1074\/jbc.R600026200","volume":"282","author":"A Lange","year":"2007","unstructured":"Lange, A. et al. Classical nuclear localization signals: definition, function, and interaction with importin alpha. J. Biol. Chem. 282, 5101\u20135105 (2007).","journal-title":"J. Biol. Chem."},{"key":"442_CR17","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/cells4030538","volume":"4","author":"A Dickmanns","year":"2015","unstructured":"Dickmanns, A., Monecke, T. & Ficner, R. Structural basis of targeting the exportin CRM1 in cancer. Cell 4, 538\u2013568 (2015).","journal-title":"Cell"},{"key":"442_CR18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0092-8674(00)80371-2","volume":"90","author":"M Fornerod","year":"1997","unstructured":"Fornerod, M., Ohno, M., Yoshida, M. & Mattaj, I. W. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90, 1051\u20131060 (1997).","journal-title":"Cell"},{"key":"442_CR19","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/36894","volume":"390","author":"M Fukuda","year":"1997","unstructured":"Fukuda, M. et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390, 308\u2013311 (1997).","journal-title":"Nature"},{"key":"442_CR20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1126\/science.278.5335.141","volume":"278","author":"B Ossareh-Nazari","year":"1997","unstructured":"Ossareh-Nazari, B., Bachelerie, F. & Dargemont, C. Evidence for a role of CRM1 in signal-mediated nuclear protein export. Science 278, 141\u2013144 (1997).","journal-title":"Science"},{"key":"442_CR21","doi-asserted-by":"crossref","first-page":"D338","DOI":"10.1093\/nar\/gks936","volume":"41","author":"SC Fu","year":"2013","unstructured":"Fu, S. C., Huang, H. C., Horton, P. & Juan, H. F. ValidNESs: a database of validated leucine-rich nuclear export signals. Nucleic Acids Res. 41, D338\u2013D343 (2013).","journal-title":"Nucleic Acids Res."},{"key":"442_CR22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/genes6010124","volume":"6","author":"M Okamura","year":"2015","unstructured":"Okamura, M., Inose, H. & Masuda, S. RNA export through the NPC in eukaryotes. Genes 6, 124\u2013149 (2015).","journal-title":"Genes"},{"key":"442_CR23","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1111\/febs.12842","volume":"281","author":"T Monecke","year":"2014","unstructured":"Monecke, T., Dickmanns, A. & Ficner, R. Allosteric control of the exportin CRM1 unraveled by crystal structure analysis. FEBS J. 281, 4179\u20134194 (2014).","journal-title":"FEBS J."},{"key":"442_CR24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0092-8674(00)80361-X","volume":"90","author":"KS Ullman","year":"1997","unstructured":"Ullman, K. S., Powers, M. A. & Forbes, D. J. Nuclear export receptors: from importin to exportin. Cell 90, 967\u2013970 (1997).","journal-title":"Cell"},{"key":"442_CR25","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/sci.2019.02.03","volume":"6","author":"AY Wang","year":"2019","unstructured":"Wang, A. Y. & Liu, H. The past, present, and future of CRM1\/XPO1 inhibitors. Stem Cell Investig. 6, 6 (2019).","journal-title":"Stem Cell Investig."},{"key":"442_CR26","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"J Schmidt","year":"2013","unstructured":"Schmidt, J. et al. Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia 27, 2357\u20132365 (2013).","journal-title":"Leukemia"},{"key":"442_CR27","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/carcin\/bgt491","volume":"35","author":"L Angus","year":"2014","unstructured":"Angus, L., van der Watt, P. J. & Leaner, V. D. Inhibition of the nuclear transporter, Kpnbeta1, results in prolonged mitotic arrest and activation of the intrinsic apoptotic pathway in cervical cancer cells. Carcinogenesis 35, 1121\u20131131 (2014).","journal-title":"Carcinogenesis"},{"key":"442_CR28","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.bbamcr.2015.05.002","volume":"1853","author":"HV Kuusisto","year":"2015","unstructured":"Kuusisto, H. V. & Jans, D. A. Hyper-dependence of breast cancer cell types on the nuclear transporter Importin \u03b21. Biochim. Biophys. Acta 1853, 1870\u20131878 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"442_CR29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/cells7110221","volume":"7","author":"FK Kosyna","year":"2018","unstructured":"Kosyna, F. K. & Depping, R. Controlling the gatekeeper: therapeutic targeting of nuclear transport. Cells 7, 221 (2018).","journal-title":"Cells"},{"key":"442_CR30","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1016\/S0021-9258(17)37374-X","volume":"269","author":"K Nishi","year":"1994","unstructured":"Nishi, K. et al. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J. Biol. Chem. 269, 6320\u20136324 (1994).","journal-title":"J. Biol. Chem."},{"key":"442_CR31","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/ja9097093","volume":"132","author":"S Bonazzi","year":"2010","unstructured":"Bonazzi, S. et al. Anguinomycins and derivatives: total syntheses, modeling, and biological evaluation of the inhibition of nucleocytoplasmic transport. J. Am. Chem. Soc. 132, 1432\u20131442 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"442_CR32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0014-4827(03)00100-9","volume":"286","author":"M Koster","year":"2003","unstructured":"Koster, M. et al. Ratjadones inhibit nuclear export by blocking CRM1\/exportin 1. Exp. Cell Res. 286, 321\u2013331 (2003).","journal-title":"Exp. Cell Res."},{"key":"442_CR33","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.bmcl.2010.03.049","volume":"20","author":"JY Wach","year":"2010","unstructured":"Wach, J. Y., Guttinger, S., Kutay, U. & Gademann, K. The cytotoxic styryl lactone goniothalamin is an inhibitor of nucleocytoplasmic transport. Bioorg. Med. Chem. Lett. 20, 2843\u20132846 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"442_CR34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5582\/ddt.v5.1.26","volume":"5","author":"K Watanabe","year":"2011","unstructured":"Watanabe, K. et al. Anti-influenza viral effects of novel nuclear export inhibitors from Valerianae Radix and Alpinia galanga. Drug Discov. Ther. 5, 26\u201331 (2011).","journal-title":"Drug Discov. Ther."},{"key":"442_CR35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/tra.12090","volume":"14","author":"M Niu","year":"2013","unstructured":"Niu, M., Wu, S., Mao, L. & Yang, Y. CRM1 is a cellular target of curcumin: new insights for the myriad of biological effects of an ancient spice. Traffic 14, 1042\u20131052 (2013).","journal-title":"Traffic"},{"key":"442_CR36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2012.10.036","volume":"144","author":"AS Azmi","year":"2013","unstructured":"Azmi, A. S. et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 144, 447\u2013456 (2013).","journal-title":"Gastroenterology"},{"key":"442_CR37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","volume":"31","author":"J Etchin","year":"2017","unstructured":"Etchin, J. et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia 31, 143\u2013150 (2017).","journal-title":"Leukemia"},{"key":"442_CR38","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/vco.12289","volume":"15","author":"JE Grayton","year":"2017","unstructured":"Grayton, J. E., Miller, T. & Wilson-Robles, H. In vitro evaluation of selective inhibitors of nuclear export (SINE) drugs KPT-185 and KPT-335 against canine mammary carcinoma and transitional cell carcinoma tumor initiating cells. Vet. Comp. Oncol. 15, 1455\u20131467 (2017).","journal-title":"Vet. Comp. Oncol."},{"key":"442_CR39","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1182\/blood-2011-01-333138","volume":"118","author":"K Sakakibara","year":"2011","unstructured":"Sakakibara, K. et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 118, 3922\u20133931 (2011).","journal-title":"Blood"},{"key":"442_CR40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","volume":"13","author":"NG Azizian","year":"2020","unstructured":"Azizian, N. G. & Li, Y. XPO1-dependent nuclear export as a target for cancer therapy. J. Hematol. Oncol. 13, 61 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"442_CR41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","volume":"74","author":"ES Newlands","year":"1996","unstructured":"Newlands, E. S., Rustin, G. J. & Brampton, M. H. Phase I trial of elactocin. Br. J. Cancer 74, 648\u2013649 (1996).","journal-title":"Br. J. Cancer"},{"key":"442_CR42","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.1217203110","volume":"110","author":"Q Sun","year":"2013","unstructured":"Sun, Q. et al. Nuclear export inhibition through covalent conjugation and hydrolysis of leptomycin B by CRM1. Proc. Natl Acad. Sci. USA 110, 1303\u20131308 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"442_CR43","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/sigtrans.2016.10","volume":"1","author":"Q Sun","year":"2016","unstructured":"Sun, Q. et al. Inhibiting cancer cell hallmark features through nuclear export inhibition. Signal Transduct. Target. Ther. 1, 16010 (2016).","journal-title":"Signal Transduct. Target. Ther."},{"key":"442_CR44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2859-13-17","volume":"13","author":"E Fleta-Soriano","year":"2014","unstructured":"Fleta-Soriano, E. et al. The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev\/CRM1-mediated nuclear export pathway. Microb. Cell Fact. 13, 17 (2014).","journal-title":"Microb. Cell Fact."},{"key":"442_CR45","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1158\/1535-7163.MCT-14-0064","volume":"13","author":"N Saito","year":"2014","unstructured":"Saito, N. et al. CBS9106-induced CRM1 degradation is mediated by cullin ring ligase activity and the neddylation pathway. Mol. Cancer Ther. 13, 3013\u20133023 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"442_CR46","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10822-012-9611-9","volume":"26","author":"O Kalid","year":"2012","unstructured":"Kalid, O., Toledo Warshaviak, D., Shechter, S., Sherman, W. & Shacham, S. Consensus induced fit docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J. Comput. Aided Mol. Des. 26, 1217\u20131228 (2012).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"442_CR47","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh, K., Cang, S., Sekhri, A. & Liu, D. Selective inhibitors of nuclear export (SINE)\u2013a novel class of anti-cancer agents. J. Hematol. Oncol. 7, 78 (2014).","journal-title":"J. Hematol. Oncol."},{"key":"442_CR48","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2012-04-423160","volume":"120","author":"P Ranganathan","year":"2012","unstructured":"Ranganathan, P. et al. Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120, 1765\u20131773 (2012).","journal-title":"Blood"},{"key":"442_CR49","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.exphem.2012.09.002","volume":"41","author":"K Zhang","year":"2013","unstructured":"Zhang, K. et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp. Hematol. 41, 67\u201378.e4 (2013).","journal-title":"Exp. Hematol."},{"key":"442_CR50","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","volume":"122","author":"CJ Walker","year":"2013","unstructured":"Walker, C. J. et al. Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 122, 3034\u20133044 (2013).","journal-title":"Blood"},{"key":"442_CR51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087585","volume":"9","author":"CA London","year":"2014","unstructured":"London, C. A. et al. Preclinical evaluation of the novel, orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study. PLoS ONE 9, e87585 (2014).","journal-title":"PLoS ONE"},{"key":"442_CR52","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1182\/blood-2012-05-429506","volume":"120","author":"R Lapalombella","year":"2012","unstructured":"Lapalombella, R. et al. Selective inhibitors of nuclear export show that CRM1\/XPO1 is a target in chronic lymphocytic leukemia. Blood 120, 4621\u20134634 (2012).","journal-title":"Blood"},{"key":"442_CR53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","volume":"27","author":"J Etchin","year":"2013","unstructured":"Etchin, J. et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 27, 66\u201374 (2013).","journal-title":"Leukemia"},{"key":"442_CR54","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","volume":"27","author":"HY Fung","year":"2014","unstructured":"Fung, H. Y. & Chook, Y. M. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin. Cancer Biol. 27, 52\u201361 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"442_CR55","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.trecan.2020.02.020","volume":"6","author":"EC Madden","year":"2020","unstructured":"Madden, E. C., Gorman, A. M., Logue, S. E. & Samali, A. Tumour cell secretome in chemoresistance and tumour recurrence. Trends Cancer 6, 489\u2013505 (2020).","journal-title":"Trends Cancer"},{"key":"442_CR56","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/sj.onc.1207302","volume":"23","author":"JA Rodriguez","year":"2004","unstructured":"Rodriguez, J. A., Schuchner, S., Au, W. W. Y., Fabbro, M. & Henderson, B. R. Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1. Oncogene 23, 1809\u20131820 (2004).","journal-title":"Oncogene"},{"key":"442_CR57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrc1274","volume":"4","author":"TR Kau","year":"2004","unstructured":"Kau, T. R., Way, J. C. & Silver, P. A. Nuclear transport and cancer: from mechanism to intervention. Nat. Rev. Cancer 4, 106\u2013117 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"442_CR58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","volume":"7","author":"P Vigneri","year":"2001","unstructured":"Vigneri, P. & Wang, J. Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med. 7, 228\u2013234 (2001).","journal-title":"Nat. Med."},{"key":"442_CR59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.drup.2003.10.004","volume":"6","author":"A O\u2019Brate","year":"2003","unstructured":"O\u2019Brate, A. & Giannakakou, P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist. Updat. 6, 313\u2013322 (2003).","journal-title":"Drug Resist. Updat."},{"key":"442_CR60","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/cancers8030035","volume":"8","author":"M El-Tanani","year":"2016","unstructured":"El-Tanani, M., Dakir, E.-H., Raynor, B. & Morgan, R. Mechanisms of nuclear export in cancer and resistance to chemotherapy. Cancers 8, 35 (2016).","journal-title":"Cancers"},{"key":"442_CR61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-017-0550-8","volume":"11","author":"AY Wang","year":"2018","unstructured":"Wang, A. Y. et al. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J. Hematol. Oncol. 11, 4 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"442_CR62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bjh.15969","volume":"186","author":"AJ Jakubowiak","year":"2019","unstructured":"Jakubowiak, A. J. et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma. Br. J. Haematol. 186, 549\u2013560 (2019).","journal-title":"Br. J. Haematol."},{"key":"442_CR63","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","volume":"7","author":"N Kalakonda","year":"2020","unstructured":"Kalakonda, N. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 7, e511\u2013e522 (2020).","journal-title":"Lancet Haematol."},{"key":"442_CR64","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12917-018-1587-9","volume":"14","author":"AR Sadowski","year":"2018","unstructured":"Sadowski, A. R. et al. Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet. Res. 14, 250 (2018).","journal-title":"BMC Vet. Res."},{"key":"442_CR65","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/1535-7163.MCT-19-0977","volume":"19","author":"TM Miyake","year":"2020","unstructured":"Miyake, T. M. et al. NRG1\/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors. Mol. Cancer Ther. 19, 1727\u20131735 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"442_CR66","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1038\/sj.bjc.6602632","volume":"92","author":"G Tonini","year":"2005","unstructured":"Tonini, G. et al. Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br. J. Cancer 92, 2225\u20132232 (2005).","journal-title":"Br. J. Cancer"},{"key":"442_CR67","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1158\/1055-9965.EPI-08-0785","volume":"18","author":"PK Dhillon","year":"2009","unstructured":"Dhillon, P. K. et al. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol. Biomarkers Prev. 18, 595\u2013600 (2009).","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"442_CR68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13000-014-0205-9","volume":"9","author":"C Takeda","year":"2014","unstructured":"Takeda, C. et al. Cytoplasmic maspin expression predicts poor prognosis of patients with soft tissue sarcomas. Diagn. Pathol. 9, 205 (2014).","journal-title":"Diagn. Pathol."},{"key":"442_CR69","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-142","volume":"14","author":"M Machowska","year":"2014","unstructured":"Machowska, M., Wachowicz, K., Sopel, M. & Rzepecki, R. Nuclear location of tumor suppressor protein maspin inhibits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells. BMC Cancer 14, 142 (2014).","journal-title":"BMC Cancer"},{"key":"442_CR70","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/bjc.2015.208","volume":"113","author":"WL Santivasi","year":"2015","unstructured":"Santivasi, W. L. et al. Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer. Br. J. Cancer 113, 453\u2013459 (2015).","journal-title":"Br. J. Cancer"},{"key":"442_CR71","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-05-3304","volume":"66","author":"FY Wu","year":"2006","unstructured":"Wu, F. Y. et al. Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity. Cancer Res. 66, 2162\u20132172 (2006).","journal-title":"Cancer Res."},{"key":"442_CR72","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.humpath.2007.10.011","volume":"39","author":"EA Rakha","year":"2008","unstructured":"Rakha, E. A. et al. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum. Pathol. 39, 857\u2013865 (2008).","journal-title":"Hum. Pathol."},{"key":"442_CR73","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/onc.2014.272","volume":"34","author":"RI Cordo Russo","year":"2015","unstructured":"Cordo Russo, R. I. et al. Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. Oncogene 34, 3413\u20133428 (2015).","journal-title":"Oncogene"},{"key":"442_CR74","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/1541-7786.MCR-18-0158","volume":"16","author":"T Sugihara","year":"2018","unstructured":"Sugihara, T. et al. YAP tyrosine phosphorylation and nuclear localization in cholangiocarcinoma cells are regulated by LCK and independent of LATS activity. Mol. Cancer Res. 16, 1556\u20131567 (2018).","journal-title":"Mol. Cancer Res."},{"key":"442_CR75","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/bloodadvances.2018016006","volume":"2","author":"JJ Ignatz-Hoover","year":"2018","unstructured":"Ignatz-Hoover, J. J. et al. Aberrant GSK3beta nuclear localization promotes AML growth and drug resistance. Blood Adv. 2, 2890\u20132903 (2018).","journal-title":"Blood Adv."},{"key":"442_CR76","first-page":"2924","volume":"8","author":"AK Sood","year":"2002","unstructured":"Sood, A. K. et al. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res. 8, 2924\u20132932 (2002).","journal-title":"Clin. Cancer Res."},{"key":"442_CR77","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2559.2005.02141.x","volume":"46","author":"G Marioni","year":"2005","unstructured":"Marioni, G. et al. Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46, 576\u2013582 (2005).","journal-title":"Histopathology"},{"key":"442_CR78","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/labinvest.2011.66","volume":"91","author":"B Goulet","year":"2011","unstructured":"Goulet, B. et al. Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab. Invest. 91, 1181\u20131187 (2011).","journal-title":"Lab. Invest."},{"key":"442_CR79","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2559.2006.02507.x","volume":"49","author":"T Narahashi","year":"2006","unstructured":"Narahashi, T. et al. Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology 49, 349\u2013357 (2006).","journal-title":"Histopathology"},{"key":"442_CR80","first-page":"1327","volume":"79","author":"DC Altieri","year":"1999","unstructured":"Altieri, D. C. & Marchisio, P. C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab. Invest. 79, 1327\u20131333 (1999).","journal-title":"Lab. Invest."},{"key":"442_CR81","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0304-3835(00)00677-7","volume":"163","author":"E Okada","year":"2001","unstructured":"Okada, E. et al. Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett. 163, 109\u2013116 (2001).","journal-title":"Cancer Lett."},{"key":"442_CR82","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00022744-200206000-00007","volume":"10","author":"R Lehner","year":"2002","unstructured":"Lehner, R. et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl. Immunohistochem. Mol. Morphol. 10, 134\u2013138 (2002).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"442_CR83","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0002-9440(10)63140-9","volume":"164","author":"A Martinez","year":"2004","unstructured":"Martinez, A. et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am. J. Pathol. 164, 501\u2013510 (2004).","journal-title":"Am. J. Pathol."},{"key":"442_CR84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.bjc.6600696","volume":"88","author":"P Grabowski","year":"2003","unstructured":"Grabowski, P. et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br. J. Cancer 88, 115\u2013119 (2003).","journal-title":"Br. J. Cancer"},{"key":"442_CR85","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2174\/092986708786242859","volume":"15","author":"JG Turner","year":"2008","unstructured":"Turner, J. G. & Sullivan, D. M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr. Med. Chem. 15, 2648\u20132655 (2008).","journal-title":"Curr. Med. Chem."},{"key":"442_CR86","doi-asserted-by":"crossref","first-page":"103504","DOI":"10.1016\/j.jprot.2019.103504","volume":"209","author":"V Chanukuppa","year":"2019","unstructured":"Chanukuppa, V. et al. XPO1 is a critical player for bortezomib resistance in multiple myeloma: a quantitative proteomic approach. J. Proteom. 209, 103504 (2019).","journal-title":"J. Proteom."},{"key":"442_CR87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/mc.22913","volume":"58","author":"S Yadav","year":"2019","unstructured":"Yadav, S. et al. SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties. Mol. Carcinog. 58, 113\u2013125 (2019).","journal-title":"Mol. Carcinog."},{"key":"442_CR88","volume":"18","author":"N Wu","year":"2018","unstructured":"Wu, N. et al. RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation. BMC Cancer 18, 67 (2018).","journal-title":"BMC Cancer"},{"key":"442_CR89","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molcel.2010.01.040","volume":"38","author":"A Kohler","year":"2010","unstructured":"Kohler, A. & Hurt, E. Gene regulation by nucleoporins and links to cancer. Mol. Cell 38, 6\u201315 (2010).","journal-title":"Mol. Cell"},{"key":"442_CR90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022423","volume":"6","author":"B David-Watine","year":"2011","unstructured":"David-Watine, B. Silencing nuclear pore protein Tpr elicits a senescent-like phenotype in cancer cells. PLoS ONE 6, e22423 (2011).","journal-title":"PLoS ONE"},{"key":"442_CR91","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.tranon.2017.04.010","volume":"10","author":"B Muz","year":"2017","unstructured":"Muz, B., Azab, F., de la Puente, P., Landesman, Y. & Azab, A. K. Selinexor overcomes hypoxia-induced drug resistance in multiple myeloma. Transl Oncol. 10, 632\u2013640 (2017).","journal-title":"Transl Oncol."},{"key":"442_CR92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7223","volume":"10","author":"N Saenz-Ponce","year":"2018","unstructured":"Saenz-Ponce, N. et al. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Sci. Transl Med. 10, eaar7223 (2018).","journal-title":"Sci. Transl Med."},{"key":"442_CR93","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coms.2014.01.001","volume":"26","author":"N Vigneswaran","year":"2014","unstructured":"Vigneswaran, N. & Williams, M. D. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac. Surg. Clin. North Am. 26, 123\u2013141 (2014).","journal-title":"Oral Maxillofac. Surg. Clin. North Am."},{"key":"442_CR94","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.oraloncology.2008.05.014","volume":"45","author":"PM Specenier","year":"2009","unstructured":"Specenier, P. M. & Vermorken, J. B. Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol. 45, 409\u2013415 (2009).","journal-title":"Oral Oncol."},{"key":"442_CR95","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med."},{"key":"442_CR96","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","volume":"9","author":"JG Turner","year":"2016","unstructured":"Turner, J. G. et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J. Hematol. Oncol. 9, 73 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"442_CR97","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7150\/jca.7080","volume":"4","author":"JG Turner","year":"2013","unstructured":"Turner, J. G. et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J. Cancer 4, 614\u2013625 (2013).","journal-title":"J. Cancer"},{"key":"442_CR98","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming, M. et al. XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of IkappaB. Mol. Cancer Ther. 17, 2564\u20132574 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"442_CR99","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"ZA Hing","year":"2015","unstructured":"Hing, Z. A. et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood 125, 3128\u20133132 (2015).","journal-title":"Blood"},{"key":"442_CR100","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","volume":"7","author":"T Kashyap","year":"2016","unstructured":"Kashyap, T. et al. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget 7, 78883\u201378895 (2016).","journal-title":"Oncotarget"},{"key":"442_CR101","doi-asserted-by":"crossref","first-page":"78896","DOI":"10.18632\/oncotarget.12969","volume":"7","author":"JG Turner","year":"2016","unstructured":"Turner, J. G. et al. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of I\u03baB\u03b1 and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget 7, 78896\u201378909 (2016).","journal-title":"Oncotarget"},{"key":"442_CR102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJM200507143530217","volume":"353","author":"JY Shih","year":"2005","unstructured":"Shih, J. Y., Gow, C. H. & Yang, P. C. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N. Engl. J. Med. 353, 207\u2013208 (2005).","journal-title":"N. Engl. J. Med."},{"key":"442_CR103","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2005.09.985","volume":"23","author":"PA Janne","year":"2005","unstructured":"Janne, P. A., Engelman, J. A. & Johnson, B. E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 23, 3227\u20133234 (2005).","journal-title":"J. Clin. Oncol."},{"key":"442_CR104","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.canlet.2017.02.029","volume":"400","author":"K Li","year":"2017","unstructured":"Li, K. et al. DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of beta-catenin. Cancer Lett. 400, 194\u2013202 (2017).","journal-title":"Cancer Lett."},{"key":"442_CR105","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1093\/nar\/24.19.3739","volume":"24","author":"GM Lamm","year":"1996","unstructured":"Lamm, G. M., Nicol, S. M., Fuller-Pace, F. V. & Lamond, A. I. p72: a human nuclear DEAD box protein highly related to p68. Nucleic Acids Res. 24, 3739\u20133747 (1996).","journal-title":"Nucleic Acids Res."},{"key":"442_CR106","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2004.09.029","volume":"119","author":"VS Yedavalli","year":"2004","unstructured":"Yedavalli, V. S., Neuveut, C., Chi, Y. H., Kleiman, L. & Jeang, K. T. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119, 381\u2013392 (2004).","journal-title":"Cell"},{"key":"442_CR107","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015).","journal-title":"N. Engl. J. Med."},{"key":"442_CR108","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/ijms21010237","volume":"21","author":"HY Khan","year":"2019","unstructured":"Khan, H. Y. et al. Targeting XPO1 and PAK4 in 8505C anaplastic thyroid cancer cells: putative implications for overcoming lenvatinib therapy resistance. Int. J. Mol. Sci. 21, 237 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"442_CR109","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","volume":"518","author":"D Juric","year":"2015","unstructured":"Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor. Nature 518, 240\u2013244 (2015).","journal-title":"Nature"},{"key":"442_CR110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","volume":"27","author":"M Elkabets","year":"2015","unstructured":"Elkabets, M. et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR\/PKC\/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 27, 533\u2013546 (2015).","journal-title":"Cancer Cell"},{"key":"442_CR111","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccr.2014.05.020","volume":"26","author":"SR Vora","year":"2014","unstructured":"Vora, S. R. et al. CDK 4\/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 26, 136\u2013149 (2014).","journal-title":"Cancer Cell"},{"key":"442_CR112","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-16-0305","volume":"6","author":"X Le","year":"2016","unstructured":"Le, X. et al. Systematic functional characterization of resistance to PI3K inhibition in breast cancer. Cancer Discov. 6, 1134\u20131147 (2016).","journal-title":"Cancer Discov."},{"key":"442_CR113","doi-asserted-by":"crossref","first-page":"F1179","DOI":"10.1152\/ajprenal.00406.2014","volume":"307","author":"M Tan","year":"2014","unstructured":"Tan, M. et al. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels. Am. J. Physiol. Renal Physiol. 307, F1179\u2013F1186 (2014).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"442_CR114","volume":"38","author":"X-L Wei","year":"2020","unstructured":"Wei, X.-L. et al. A first-in-human phase I study of CYH33, a phosphatidylinositol 3-kinase (PI3K) \u03b1 selective inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 38, e15645 (2020).","journal-title":"J. Clin. Oncol."},{"key":"442_CR115","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.canlet.2018.07.011","volume":"433","author":"XL Liu","year":"2018","unstructured":"Liu, X. L. et al. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kalpha-selective inhibitor CYH33 in breast cancer. Cancer Lett. 433, 273\u2013282 (2018).","journal-title":"Cancer Lett."},{"key":"442_CR116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-019-0085-2","volume":"4","author":"XL Liu","year":"2019","unstructured":"Liu, X. L. et al. Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kalpha inhibition in breast cancer. Signal Transduct. Target. Ther. 4, 49 (2019).","journal-title":"Signal Transduct. Target. Ther."},{"key":"442_CR117","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neo.2019.06.001","volume":"21","author":"H Kawai","year":"2019","unstructured":"Kawai, H. et al. Overcoming tyrosine kinase inhibitor resistance in transformed cell harboring SEPT9-ABL1 chimeric fusion protein. Neoplasia 21, 788\u2013801 (2019).","journal-title":"Neoplasia"},{"key":"442_CR118","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41420-018-0049-2","volume":"4","author":"D Nie","year":"2018","unstructured":"Nie, D. et al. KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to imatinib. Cell Death Discov. 4, 48 (2018).","journal-title":"Cell Death Discov."},{"key":"442_CR119","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","volume":"37","author":"E Pujade-Lauraine","year":"2019","unstructured":"Pujade-Lauraine, E., Banerjee, S. & Pignata, S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J. Clin. Oncol. 37, 2437\u20132448 (2019).","journal-title":"J. Clin. Oncol."},{"key":"442_CR120","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1080\/15216540701636287","volume":"59","author":"B Stordal","year":"2007","unstructured":"Stordal, B. & Davey, M. Understanding cisplatin resistance using cellular models. IUBMB Life 59, 696\u2013699 (2007).","journal-title":"IUBMB Life"},{"key":"442_CR121","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.18632\/oncotarget.25637","volume":"9","author":"T Kashyap","year":"2018","unstructured":"Kashyap, T. et al. Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents. Oncotarget 9, 30773\u201330786 (2018).","journal-title":"Oncotarget"},{"key":"442_CR122","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","volume":"22","author":"P Ranganathan","year":"2016","unstructured":"Ranganathan, P. et al. XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus. Clin. Cancer Res. 22, 6142\u20136152 (2016).","journal-title":"Clin. Cancer Res."},{"key":"442_CR123","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-16-1333","volume":"23","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer. Clin. Cancer Res. 23, 1552\u20131563 (2017).","journal-title":"Clin. Cancer Res."},{"key":"442_CR124","doi-asserted-by":"crossref","first-page":"17468","DOI":"10.1073\/pnas.1111138108","volume":"108","author":"M Yamamoto-Sugitani","year":"2011","unstructured":"Yamamoto-Sugitani, M. et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc. Natl Acad. Sci. USA 108, 17468\u201317473 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"442_CR125","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/leu.2013.175","volume":"27","author":"F Fei","year":"2013","unstructured":"Fei, F. et al. Galectin-3 in pre-B acute lymphoblastic leukemia. Leukemia 27, 2385\u20132388 (2013).","journal-title":"Leukemia"},{"key":"442_CR126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-014-0099-8","volume":"8","author":"K Hu","year":"2015","unstructured":"Hu, K. et al. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt\/beta-catenin signaling pathway. J. Hematol. Oncol. 8, 1 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"442_CR127","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bbagen.2009.07.005","volume":"1800","author":"KC Haudek","year":"2010","unstructured":"Haudek, K. C. et al. Dynamics of galectin-3 in the nucleus and cytoplasm. Biochim. Biophys. Acta 1800, 181\u2013189 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"442_CR128","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/1535-7163.MCT-15-0104","volume":"14","author":"S Kazim","year":"2015","unstructured":"Kazim, S. et al. Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic cancer. Mol. Cancer Ther. 14, 1570\u20131581 (2015).","journal-title":"Mol. Cancer Ther."},{"key":"442_CR129","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/cancers9110157","volume":"9","author":"M Amrutkar","year":"2017","unstructured":"Amrutkar, M. & Gladhaug, I. P. Pancreatic cancer chemoresistance to gemcitabine. Cancers 9, 157 (2017).","journal-title":"Cancers"},{"key":"442_CR130","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.ejca.2011.10.035","volume":"48","author":"MM Vickers","year":"2012","unstructured":"Vickers, M. M. et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur. J. Cancer 48, 1434\u20131442 (2012).","journal-title":"Eur. J. Cancer"},{"key":"442_CR131","first-page":"23","volume":"4","author":"A Recht","year":"1990","unstructured":"Recht, A. & Harris, J. R. Selection of patients with early-stage breast cancer for conservative surgery and radiation. Oncology 4, 23\u201330 (1990).","journal-title":"Oncology"},{"key":"442_CR132","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/s41416-020-0846-2","volume":"122","author":"PG Corrie","year":"2020","unstructured":"Corrie, P. G. et al. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Br. J. Cancer 122, 1760\u20131768 (2020).","journal-title":"Br. J. Cancer"},{"key":"442_CR133","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2671-9","volume":"16","author":"F De Vita","year":"2016","unstructured":"De Vita, F. et al. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer 16, 709 (2016).","journal-title":"BMC Cancer"},{"key":"442_CR134","first-page":"5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"Phi, L. T. H. et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cell Int. 2018, 5416923 (2018).","journal-title":"Stem Cell Int."},{"key":"442_CR135","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1158\/1078-0432.CCR-19-1728","volume":"26","author":"AS Azmi","year":"2020","unstructured":"Azmi, A. S. et al. Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 26, 1338\u20131348 (2020).","journal-title":"Clin. Cancer Res."},{"key":"442_CR136","doi-asserted-by":"crossref","first-page":"E478","DOI":"10.1002\/ajh.24496","volume":"91","author":"P Jain","year":"2016","unstructured":"Jain, P. et al. Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am. J. Hematol. 91, E478\u2013E479 (2016).","journal-title":"Am. J. Hematol."},{"key":"442_CR137","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","volume":"34","author":"AR Abdul Razak","year":"2016","unstructured":"Abdul Razak, A. R. et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J. Clin. Oncol. 34, 4142\u20134150 (2016).","journal-title":"J. Clin. Oncol."},{"key":"442_CR138","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"F Jardin","year":"2016","unstructured":"Jardin, F. et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am. J. Hematol. 91, 923\u2013930 (2016).","journal-title":"Am. J. Hematol."},{"key":"442_CR139","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.canlet.2016.09.016","volume":"383","author":"I Muqbil","year":"2016","unstructured":"Muqbil, I. et al. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Lett. 383, 309\u2013317 (2016).","journal-title":"Cancer Lett."},{"key":"442_CR140","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","volume":"131","author":"C Chen","year":"2018","unstructured":"Chen, C. et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. Blood 131, 855\u2013863 (2018).","journal-title":"Blood"},{"key":"442_CR141","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2017.75.5207","volume":"36","author":"DT Vogl","year":"2018","unstructured":"Vogl, D. T. et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J. Clin. Oncol. 36, 859\u2013866 (2018).","journal-title":"J. Clin. Oncol."},{"key":"442_CR142","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari, A. et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 381, 727\u2013738 (2019).","journal-title":"N. Engl. J. Med."},{"key":"442_CR143","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","volume":"21","author":"K Podar","year":"2020","unstructured":"Podar, K., Shah, J., Chari, A., Richardson, P. G. & Jagannath, S. Selinexor for the treatment of multiple myeloma. Expert. Opin. Pharmacother. 21, 399\u2013408 (2020).","journal-title":"Expert. Opin. Pharmacother."},{"key":"442_CR144","unstructured":"ASH Clinical news. FDA Grants Selinexor Accelerated Approval Despite Concerns with Trial Data https:\/\/www.ashclinicalnews.org\/online-exclusives\/fda-grants-selinexor-accelerated-approval-despite-concerns-trial-data\/#:~:text=The%20U.S.%20Food%20and%20Drug,treatment%20with%20two%20or%20mor (2019)."},{"key":"442_CR145","unstructured":"US Food & Drug Administration. FDA grants accelerated approval to selinexor for multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-selinexor-multiple-myeloma (2019)."},{"key":"442_CR146","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1182\/blood-2018-06-858852","volume":"132","author":"NJ Bahlis","year":"2018","unstructured":"Bahlis, N. J. et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood 132, 2546\u20132554 (2018).","journal-title":"Blood"},{"key":"442_CR147","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/JCO.2020.38.15_suppl.8501","volume":"38","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos, M. Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. J. Clin. Oncol. 38, 8501 (2020).","journal-title":"J. Clin. Oncol."},{"key":"442_CR148","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel, J. S. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 1055\u20131066 (2013).","journal-title":"Lancet Oncol."},{"key":"442_CR149","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2019-122907","volume":"134","author":"CI Chen","year":"2019","unstructured":"Chen, C. I. et al. Selinexor, pomalidomide, and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma. Blood 134, 141\u2013141 (2019).","journal-title":"Blood"},{"key":"442_CR150","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41375-020-0756-6","volume":"34","author":"M Gavriatopoulou","year":"2020","unstructured":"Gavriatopoulou, M. et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia 34, 2430\u20132440 (2020).","journal-title":"Leukemia"},{"key":"442_CR151","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres, A. et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126, 2798\u20132804 (2015).","journal-title":"Blood"},{"key":"442_CR152","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N. Engl. J. Med. 372, 311\u2013319 (2015).","journal-title":"N. Engl. J. Med."},{"key":"442_CR153","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","volume":"129","author":"J Kuruvilla","year":"2017","unstructured":"Kuruvilla, J. et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 129, 3175\u20133183 (2017).","journal-title":"Blood"},{"key":"442_CR154","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","volume":"129","author":"R Garzon","year":"2017","unstructured":"Garzon, R. et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood 129, 3165\u20133174 (2017).","journal-title":"Blood"},{"key":"442_CR155","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1111\/bjh.16804","volume":"190","author":"W Fiedler","year":"2020","unstructured":"Fiedler, W. et al. A phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed\/refractory acute myeloid leukaemia. Br. J. Haematol. 190, e169\u2013e173 (2020).","journal-title":"Br. J. Haematol."},{"key":"442_CR156","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V128.22.341.341","volume":"128","author":"W Fiedler","year":"2016","unstructured":"Fiedler, W. et al. Phase II results of ara-C and idarubicin in combination with the selective inhibitor of nuclear export (SINE) compound selinexor (KPT-330) in patients with relapsed or refractory AML. Blood 128, 341 (2016).","journal-title":"Blood"},{"key":"442_CR157","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","volume":"34","author":"TB Alexander","year":"2016","unstructured":"Alexander, T. B. et al. Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia. J. Clin. Oncol. 34, 4094\u20134101 (2016).","journal-title":"J. Clin. Oncol."},{"key":"442_CR158","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus, V., Miloudi, H., Taly, A., Sola, B. & Jardin, F. XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J. Hematol. Oncol. 10, 47 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"442_CR159","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","volume":"30","author":"ZA Hing","year":"2016","unstructured":"Hing, Z. A. et al. Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia 30, 2364\u20132372 (2016).","journal-title":"Leukemia"},{"key":"442_CR160","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1182\/blood-2014-10-607648","volume":"125","author":"P Ranganathan","year":"2015","unstructured":"Ranganathan, P. et al. Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood 125, 2689\u20132692 (2015).","journal-title":"Blood"},{"key":"442_CR161","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","volume":"34","author":"MM Gounder","year":"2016","unstructured":"Gounder, M. M. et al. Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma. J. Clin. Oncol. 34, 3166\u20133174 (2016).","journal-title":"J. Clin. Oncol."},{"key":"442_CR162","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","volume":"18","author":"UH Gandhi","year":"2018","unstructured":"Gandhi, U. H. et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin. Lymphoma Myeloma Leuk. 18, 335\u2013345 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"442_CR163","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2014.04.005","volume":"27","author":"WT Senapedis","year":"2014","unstructured":"Senapedis, W. T., Baloglu, E. & Landesman, Y. Clinical translation of nuclear export inhibitors in cancer. Semin. Cancer Biol. 27, 74\u201386 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"442_CR164","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semcancer.2016.01.002","volume":"36","author":"A Sukari","year":"2016","unstructured":"Sukari, A., Muqbil, I., Mohammad, R. M., Philip, P. A. & Azmi, A. S. F-BOX proteins in cancer cachexia and muscle wasting: emerging regulators and therapeutic opportunities. Semin. Cancer Biol. 36, 95\u2013104 (2016).","journal-title":"Semin. Cancer Biol."},{"key":"442_CR165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymthe.2019.08.016","volume":"28","author":"RM Hightower","year":"2020","unstructured":"Hightower, R. M. et al. The SINE compound KPT-350 blocks dystrophic pathologies in DMD zebrafish and mice. Mol. Ther. 28, 189\u2013201 (2020).","journal-title":"Mol. Ther."},{"key":"442_CR166","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 28, 155\u2013165 (2014).","journal-title":"Leukemia"},{"key":"442_CR167","doi-asserted-by":"publisher","unstructured":"Maracaja, D. L. V. et al. EBV-positive primary large B-cell lymphoma: the role of immunohistochemistry and XPO1 in the diagnosis of mediastinal lymphomas. Appl. Immunohistochem. Mol. Morphol. https:\/\/doi.org\/10.1097\/PAI.0000000000000820 (2019).","DOI":"10.1097\/PAI.0000000000000820"},{"key":"442_CR168","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1007\/s00018-016-2292-0","volume":"73","author":"I Garc\u00eda-Santisteban","year":"2016","unstructured":"Garc\u00eda-Santisteban, I. et al. A cellular reporter to evaluate CRM1 nuclear export activity: functional analysis of the cancer-related mutant E571K. Cell Mol. Life Sci. 73, 4685\u20134699 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"442_CR169","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1091\/mbc.E20-04-0233","volume":"31","author":"JM Baumhardt","year":"2020","unstructured":"Baumhardt, J. M. et al. Recognition of nuclear export signals by CRM1 carrying the oncogenic E571K mutation. Mol. Biol. Cell 31, 1871\u20131891 (2020).","journal-title":"Mol. Biol. Cell"},{"key":"442_CR170","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","volume":"101","author":"V Camus","year":"2016","unstructured":"Camus, V. et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 101, 1094\u20131101 (2016).","journal-title":"Haematologica"},{"key":"442_CR171","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"S Jeromin","year":"2014","unstructured":"Jeromin, S. et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia 28, 108\u2013117 (2014).","journal-title":"Leukemia"},{"key":"442_CR172","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gpb.2017.09.004","volume":"16","author":"K Wu","year":"2018","unstructured":"Wu, K., He, J., Pu, W. & Peng, Y. The role of exportin-5 in microRNA biogenesis and cancer. Genomics Proteom. Bioinforma. 16, 120\u2013126 (2018).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"442_CR173","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1093\/nar\/gky306","volume":"46","author":"P Sheng","year":"2018","unstructured":"Sheng, P. et al. Dicer cleaves 5\u2019-extended microRNA precursors originating from RNA polymerase II transcription start sites. Nucleic Acids Res. 46, 5737\u20135752 (2018).","journal-title":"Nucleic Acids Res."},{"key":"442_CR174","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.cell.2013.11.027","volume":"155","author":"M Xie","year":"2013","unstructured":"Xie, M. et al. Mammalian 5\u2019-capped microRNA precursors that generate a single microRNA. Cell 155, 1568\u20131580 (2013).","journal-title":"Cell"},{"key":"442_CR175","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2174\/1389450111314100002","volume":"14","author":"I Muqbil","year":"2013","unstructured":"Muqbil, I., Bao, B., Abou-Samra, A. B., Mohammad, R. M. & Azmi, A. S. Nuclear export mediated regulation of microRNAs: potential target for drug intervention. Curr. Drug Targets 14, 1094\u20131100 (2013).","journal-title":"Curr. Drug Targets"},{"key":"442_CR176","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/cancers11081101","volume":"11","author":"AS Azmi","year":"2019","unstructured":"Azmi, A. S. et al. DNA-methylation-caused downregulation of miR-30 contributes to the high expression of XPO1 and the aggressive growth of tumors in pancreatic ductal adenocarcinoma. Cancers 11, 1101 (2019).","journal-title":"Cancers"},{"key":"442_CR177","doi-asserted-by":"crossref","first-page":"82144","DOI":"10.18632\/oncotarget.19285","volume":"8","author":"AS Azmi","year":"2017","unstructured":"Azmi, A. S. et al. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget 8, 82144\u201382155 (2017).","journal-title":"Oncotarget"},{"key":"442_CR178","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.3390\/ijms20194826","volume":"20","author":"R Sexton","year":"2019","unstructured":"Sexton, R. et al. Targeting nuclear exporter protein XPO1\/CRM1 in gastric cancer. Int. J. Mol. Sci. 20, 4826 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"442_CR179","doi-asserted-by":"crossref","first-page":"E4961","DOI":"10.1073\/pnas.1618732114","volume":"114","author":"I Martinez","year":"2017","unstructured":"Martinez, I. et al. An exportin-1-dependent microRNA biogenesis pathway during human cell quiescence. Proc. Natl Acad. Sci. USA 114, E4961\u2013E4970 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"442_CR180","first-page":"9","volume":"2","author":"D Leaderer","year":"2011","unstructured":"Leaderer, D. et al. Genetic and epigenetic association studies suggest a role of microRNA biogenesis gene exportin-5 (XPO5) in breast tumorigenesis. Int. J. Mol. Epidemiol. Genet. 2, 9\u201318 (2011).","journal-title":"Int. J. Mol. Epidemiol. Genet."},{"key":"442_CR181","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","volume":"121","author":"K Kojima","year":"2013","unstructured":"Kojima, K. et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121, 4166\u20134174 (2013).","journal-title":"Blood"},{"key":"442_CR182","doi-asserted-by":"crossref","first-page":"7473","DOI":"10.1073\/pnas.1002650107","volume":"107","author":"W Blum","year":"2010","unstructured":"Blum, W. et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc. Natl Acad. Sci. USA 107, 7473\u20137478 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"442_CR183","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3390\/cancers12061574","volume":"12","author":"LT Brinton","year":"2020","unstructured":"Brinton, L. T. et al. Cotargeting of XPO1 enhances the antileukemic activity of midostaurin and gilteritinib in acute myeloid leukemia. Cancers 12, 1574 (2020).","journal-title":"Cancers"},{"key":"442_CR184","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1182\/blood-2007-10-121137","volume":"111","author":"L Yu","year":"2008","unstructured":"Yu, L. et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-\u03baB. Blood 111, 4617\u20134626 (2008).","journal-title":"Blood"},{"key":"442_CR185","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286\u20132294 (2014).","journal-title":"N. Engl. J. Med."},{"key":"442_CR186","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-019-0803-9","volume":"12","author":"Y Liu","year":"2019","unstructured":"Liu, Y., Azizian, N. G., Dou, Y., Pham, L. V. & Li, Y. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. J. Hematol. Oncol. 12, 119 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"442_CR187","volume":"20","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-\u03baB signaling pathway. Cancer Cell Int. 20, 97 (2020).","journal-title":"Cancer Cell Int."},{"key":"442_CR188","doi-asserted-by":"crossref","first-page":"P355","DOI":"10.1186\/2051-1426-3-S2-P355","volume":"3 (Suppl. 2)","author":"MR Farren","year":"2015","unstructured":"Farren, M. R. et al. Selinexor, a selective inhibitor of nuclear export (SINE), shows enhanced activity in combination with PD-1\/PD-L1 blockade in syngeneic murine models of colon cancer and melanoma. J. Immunother. Cancer 3 (Suppl. 2), P355 (2015).","journal-title":"J. Immunother. Cancer"},{"key":"442_CR189","volume":"10","author":"ZC Zhu","year":"2019","unstructured":"Zhu, Z. C., Liu, J. W., Yang, C., Zhao, M. & Xiong, Z. Q. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis. Cell Death Dis. 10, 395 (2019).","journal-title":"Cell Death Dis."},{"key":"442_CR190","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948150","volume":"20","author":"AP Martin","year":"2019","unstructured":"Martin, A. P. et al. STK38 kinase acts as XPO1 gatekeeper regulating the nuclear export of autophagy proteins and other cargoes. EMBO Rep. 20, e48150 (2019).","journal-title":"EMBO Rep."},{"key":"442_CR191","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.11466","volume":"4","author":"K Kirli","year":"2015","unstructured":"Kirli, K. et al. A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning. eLife 4, e11466 (2015).","journal-title":"eLife"},{"key":"442_CR192","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"442_CR193","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner, L. A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl Acad. Sci. USA 111, 2349\u20132354 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"442_CR194","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrg.2017.97","volume":"19","author":"JG Doench","year":"2018","unstructured":"Doench, J. G. Am I ready for CRISPR? A user\u2019s guide to genetic screens. Nat. Rev. Genet. 19, 67\u201380 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"442_CR195","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3324\/haematol.2017.185082","volume":"103","author":"W Zhang","year":"2018","unstructured":"Zhang, W. et al. Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103, 1642\u20131653 (2018).","journal-title":"Haematologica"},{"key":"442_CR196","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10428194.2019.1665664","volume":"61","author":"B Bhatnagar","year":"2020","unstructured":"Bhatnagar, B. et al. Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leuk. Lymphoma 61, 387\u2013396 (2020).","journal-title":"Leuk. Lymphoma"},{"key":"442_CR197","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1634\/theoncologist.2017-0624","volume":"23","author":"XX Wei","year":"2018","unstructured":"Wei, X. X. et al. A phase II trial of selinexor, an oral selective inhibitor of nuclear export compound, in abiraterone- and\/or enzalutamide-refractory metastatic castration-resistant prostate cancer. Oncologist 23, 656\u2013e64 (2018).","journal-title":"Oncologist"},{"key":"442_CR198","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1634\/theoncologist.2019-0231","volume":"24","author":"M Shafique","year":"2019","unstructured":"Shafique, M. et al. A phase II trial of selinexor (KPT-330) for metastatic triple-negative breast cancer. Oncologist 24, 887\u2013e416 (2019).","journal-title":"Oncologist"},{"key":"442_CR199","doi-asserted-by":"publisher","DOI":"10.2174\/1568009620666200628105727","author":"S Nilsson","year":"2020","unstructured":"Nilsson, S. et al. Selinexor (KPT-330), an oral selective inhibitor of nuclear export (SINE) compound, in combination with FOLFOX in patients with metastatic colorectal cancer (mCRC) - final results of the phase I trial SENTINEL. Curr. Cancer Drug Targets https:\/\/doi.org\/10.2174\/1568009620666200628105727 (2020).","journal-title":"Curr. Cancer Drug Targets"},{"key":"442_CR200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ygyno.2019.11.012","volume":"156","author":"IB Vergote","year":"2020","unstructured":"Vergote, I. B. et al. Phase 2 study of the exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol. Oncol. 156, 308\u2013314 (2020).","journal-title":"Gynecol. Oncol."},{"key":"442_CR201","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/jco.2015.33.15_suppl.2542","volume":"33","author":"DSP Tan","year":"2015","unstructured":"Tan, D. S. P. et al. Phase I study of the safety and tolerability of the exportin 1 (XPO1) inhibitor selinexor (SXR) in Asian patients (pts) with advanced solid cancers. J. Clin. Oncol. 33, 2542\u20132542 (2015).","journal-title":"J. Clin. Oncol."},{"key":"442_CR202","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.2019.37.15_suppl.2005","volume":"37","author":"AB Lassman","year":"2019","unstructured":"Lassman, A. B. et al. Efficacy and safety of selinexor in recurrent glioblastoma. J. Clin. Oncol. 37, 2005\u20132005 (2019).","journal-title":"J. Clin. Oncol."},{"key":"442_CR203","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1172\/JCI97117","volume":"128","author":"X Gu","year":"2018","unstructured":"Gu, X. et al. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J. Clin. Invest. 128, 4260\u20134279 (2018).","journal-title":"J. Clin. Invest."},{"key":"442_CR204","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-17-1303","volume":"17","author":"A Wahba","year":"2018","unstructured":"Wahba, A., Rath, B. H., O\u2019Neill, J. W., Camphausen, K. & Tofilon, P. J. The XPO1 inhibitor selinexor inhibits translation and enhances the radiosensitivity of glioblastoma cells grown in vitro and in vivo. Mol. Cancer Ther. 17, 1717\u20131726 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"442_CR205","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1200\/JCO.2005.05.3348","volume":"24","author":"AD Colevas","year":"2006","unstructured":"Colevas, A. D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 24, 2644\u20132652 (2006).","journal-title":"J. Clin. Oncol."},{"key":"442_CR206","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/jjco\/hyn052","volume":"38","author":"TF Wang","year":"2008","unstructured":"Wang, T. F., Chu, S. C., Kao, R. H., Yao, C. Y. & Li, C. C. A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck. Jpn. J. Clin. Oncol. 38, 459\u2013463 (2008).","journal-title":"Jpn. J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1038\/s41571-020-00454-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:00:00Z","timestamp":1606176000000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-00442-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-00442-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-020-00442-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:43:26Z","timestamp":1684619006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-020-00442-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,10]]},"references-count":206,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["442"],"URL":"https:\/\/doi.org\/10.1038\/s41571-020-00442-4","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41571-020-00454-0","asserted-by":"object"}]},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,10]]},"assertion":[{"value":"8 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-020-00454-0","URL":"https:\/\/doi.org\/10.1038\/s41571-020-00454-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.S.A. has acted as a consultant of GLG Consulting and GuidePoint, has received research grants from EISAI Janssen and Rhizen and has been a speaker at an event organized by Karyopharm. The author\u2019s institution has received research funding (partially supporting the phase Ib\/II studies NCT02178436 and NCT03147885) from Karyopharm. M.H.U. and R.M.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}